BAKER BROS. ADVISORS LP
CIK 1263508 · last filed 2026-07-02
BAKER BROS. ADVISORS LP is a corporate insider who has filed 94 SEC Form 4 insider transactions across 25 companies since 2012. The most recent filing, for KOD, was dated Jul 2, 2026. Across all open-market trades the lifetime net is +$3.38B, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.93B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.93B
25
94
$3.38B
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KOD | Director | 15,316,021 | $39.94 | $611.72M | $106.09M | 5 | 2026-07-02 |
| PRLD | Director | — | $4.68 | — | $0 | 2 | 2026-04-22 |
| BCYC | Director | 937,483 | $3.95 | $3.70M | $0 | 1 | 2026-01-06 |
| KALA | 930 | $0.65 | $605 | -$4.23M | 1 | 2025-10-02 | |
| KYMR | Director | 534,134 | $106.89 | $57.10M | $173.05M | 2 | 2025-06-30 |
| ACAD | Director | 39,468,841 | $26.04 | $1.03B | $1.96B | 10 | 2025-06-02 |
| INCY | Director | 314,600 | $131.75 | $41.45M | $1.09B | 11 | 2025-04-02 |
| IMCR | Director | 2,144,060 | $33.53 | $71.89M | $143.96M | 2 | 2025-03-19 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 136,517 | $184.71 | $25.22M | -$1.48B | 8 | 2024-12-10 |
| MDGL | Director | 179,279 | $540.18 | $96.84M | $135.10M | 3 | 2024-03-25 |
| Atreca, Inc. (BCEL) Delisted | 2,971,128 | $0.15 | $445.7K | -$442.3K | 1 | 2023-10-23 | |
| TCRX | Director | — | $0.77 | — | $0 | 1 | 2023-06-15 |
| Seagen Inc. (SGEN) Delisted | Director | 42,989,787 | $228.74 | $9.83B | $955.17M | 9 | 2022-05-17 |
| KNSA | Director | — | $80.05 | — | $0 | 2 | 2020-07-02 |
| Neurogene Inc. (NLTX) Delisted | Director | — | $13.96 | — | $0 | 1 | 2019-10-15 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 2,883,204 | $1.27 | $3.66M | $301.82M | 1 | 2019-09-20 |
| Aceragen, Inc. (IDRA) Delisted | Director | 253,701 | $7.22 | $1.83M | $45.50M | 4 | 2019-07-03 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 7,641,248 | — | — | -$413.77M | 10 | 2019-06-18 |
| HOOKIPA Pharma Inc. (HOOK) Delisted | 82,073 | $1.15 | $94.4K | $50.00M | 1 | 2019-04-23 | |
| Mirati Therapeutics, Inc. (MRTX) Delisted | 10%+ Owner | 2,372,355 | $58.70 | $139.26M | $28.00M | 2 | 2017-11-13 |
| Neurogene Inc. (AQXP) Delisted | Director | 9,412,424 | — | — | $170.50M | 4 | 2017-05-09 |
| BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | 10%+ Owner | 43,476 | $0.07 | $3.3K | $8.00M | 1 | 2017-03-28 |
| Invitae Corp (NVTA) Delisted | 10%+ Owner | 734,261 | $0.09 | $65.4K | $17.60M | 1 | 2016-11-18 |
| BCRX | 10%+ Owner | 1,680,147 | $9.74 | $16.37M | -$65.62M | 3 | 2016-08-16 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 0 | — | — | $158.62M | 2 | 2015-06-23 |
Recent Filings
94 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-02 | KOD | Grant (A) | — | $0 | EDGAR |
| 2026-04-22 | PRLD | Buy (P) | — | $0 | EDGAR |
| 2026-01-06 | BCYC | Grant (A) | +228,000 | $0 | EDGAR |
| 2025-10-02 | KALA | Sell (S) | −2,921,632 | -$4.23M | EDGAR |
| 2025-08-18 | — | U | −24,722,460 | $0 | |
| 2025-06-30 | KYMR | Buy (P) | +3,933,000 | $173.05M | EDGAR |
| 2025-06-02 | ACAD | Grant (A) | +194,568 | $0 | EDGAR |
| 2025-04-02 | INCY | Grant (A) | +5,844 | $0 | EDGAR |
| 2025-03-19 | IMCR | Mixed | +4,844,028 | $143.96M | EDGAR |
| 2024-12-10 | BeOne Medicines Ltd. (BGNE) Delisted | Sell (S) | −6,222,102 | -$1.17B | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.